Tags

Type your tag names separated by a space and hit enter

Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Arthritis Rheum. 2005 Sep; 52(9):2889-96.AR

Abstract

OBJECTIVE

To clarify the clinical significance of serum levels of pulmonary and activation-regulated chemokine (PARC) in the diagnosis and monitoring of pulmonary fibrosis (PF) in patients with systemic sclerosis (SSc) and to compare PARC levels with KL-6 antigen or surfactant protein D (SP-D) levels.

METHODS

Serum PARC levels were determined by enzyme-linked immunosorbent assay in 123 SSc patients. In a retrospective longitudinal study, correlation of serum PARC levels with the activity of PF was assessed in 21 SSc patients with active PF.

RESULTS

PARC levels at the first visit were higher in patients with SSc than in patients with systemic lupus erythematosus (SLE) or healthy controls. Increased serum PARC levels were associated with involvement of PF, decreased diffusing capacity for carbon monoxide, and decreased vital capacity in SSc patients. In the longitudinal study, serum PARC levels were significantly decreased in SSc patients with inactive PF compared with those with active PF.

CONCLUSION

Elevated serum PARC levels correlated with PF and more sensitively reflected the PF activity than did serum KL-6 or SP-D levels in SSc. Serum PARC levels may be a useful new serum marker for active PF in SSc.

Authors+Show Affiliations

Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16142750

Citation

Kodera, Masanari, et al. "Serum Pulmonary and Activation-regulated chemokine/CCL18 Levels in Patients With Systemic Sclerosis: a Sensitive Indicator of Active Pulmonary Fibrosis." Arthritis and Rheumatism, vol. 52, no. 9, 2005, pp. 2889-96.
Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005;52(9):2889-96.
Kodera, M., Hasegawa, M., Komura, K., Yanaba, K., Takehara, K., & Sato, S. (2005). Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis and Rheumatism, 52(9), 2889-96.
Kodera M, et al. Serum Pulmonary and Activation-regulated chemokine/CCL18 Levels in Patients With Systemic Sclerosis: a Sensitive Indicator of Active Pulmonary Fibrosis. Arthritis Rheum. 2005;52(9):2889-96. PubMed PMID: 16142750.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. AU - Kodera,Masanari, AU - Hasegawa,Minoru, AU - Komura,Kazuhiro, AU - Yanaba,Koichi, AU - Takehara,Kazuhiko, AU - Sato,Shinichi, PY - 2005/9/6/pubmed PY - 2005/11/3/medline PY - 2005/9/6/entrez SP - 2889 EP - 96 JF - Arthritis and rheumatism JO - Arthritis Rheum VL - 52 IS - 9 N2 - OBJECTIVE: To clarify the clinical significance of serum levels of pulmonary and activation-regulated chemokine (PARC) in the diagnosis and monitoring of pulmonary fibrosis (PF) in patients with systemic sclerosis (SSc) and to compare PARC levels with KL-6 antigen or surfactant protein D (SP-D) levels. METHODS: Serum PARC levels were determined by enzyme-linked immunosorbent assay in 123 SSc patients. In a retrospective longitudinal study, correlation of serum PARC levels with the activity of PF was assessed in 21 SSc patients with active PF. RESULTS: PARC levels at the first visit were higher in patients with SSc than in patients with systemic lupus erythematosus (SLE) or healthy controls. Increased serum PARC levels were associated with involvement of PF, decreased diffusing capacity for carbon monoxide, and decreased vital capacity in SSc patients. In the longitudinal study, serum PARC levels were significantly decreased in SSc patients with inactive PF compared with those with active PF. CONCLUSION: Elevated serum PARC levels correlated with PF and more sensitively reflected the PF activity than did serum KL-6 or SP-D levels in SSc. Serum PARC levels may be a useful new serum marker for active PF in SSc. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/16142750/Serum_pulmonary_and_activation_regulated_chemokine/CCL18_levels_in_patients_with_systemic_sclerosis:_a_sensitive_indicator_of_active_pulmonary_fibrosis_ L2 - https://doi.org/10.1002/art.21257 DB - PRIME DP - Unbound Medicine ER -